OMO-1 in Solid Malignancies

NCT03138083 PHASE1, PHASE2 TERMINATED

This is a modular, first time in patient, open-label, multicentre study of OMO-1, administered orally, alone and in combination with anti-cancer treatments, in patients with locally advanced, unresectable or metastatic solid malignancies.

Details

Lead sponsor	Octimet Oncology N.V.
Phase	PHASE1, PHASE2
Status	TERMINATED
Enrolment	40
Start date	Tue Aug 08 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon May 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Neoplasms

Interventions

• OMO-1

Countries

France, Netherlands, Belgium, United Kingdom, United States